XTL Operating Cycle from 2010 to 2026
| XTLB Stock | USD 1.06 0.01 0.93% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 72.11 | Current Value 68.5 | Quarterly Volatility 4.6 M |
Check XTL Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XTL Biopharmaceutica's main balance sheet or income statement drivers, such as Other Operating Expenses of 2.2 M, Research Development of 83.8 K or Total Operating Expenses of 1.9 M, as well as many indicators such as Price To Sales Ratio of 25.16, Dividend Yield of 0.0 or PTB Ratio of 2.67. XTL financial statements analysis is a perfect complement when working with XTL Biopharmaceutica Valuation or Volatility modules.
XTL | Operating Cycle | Build AI portfolio with XTL Stock |
Analyzing XTL Biopharmaceutica's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing XTL Biopharmaceutica's current valuation and future prospects.
Latest XTL Biopharmaceutica's Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of XTL Biopharmaceuticals Ltd over the last few years. It is XTL Biopharmaceutica's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XTL Biopharmaceutica's overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
XTL Operating Cycle Regression Statistics
| Arithmetic Mean | 1,126,677 | |
| Geometric Mean | 198.22 | |
| Coefficient Of Variation | 412.27 | |
| Mean Deviation | 2,120,599 | |
| Median | 80.12 | |
| Standard Deviation | 4,644,959 | |
| Sample Variance | 21.6T | |
| Range | 19.2M | |
| R-Value | (0.20) | |
| Mean Square Error | 22.1T | |
| R-Squared | 0.04 | |
| Significance | 0.43 | |
| Slope | (187,769) | |
| Total Sum of Squares | 345.2T |
XTL Operating Cycle History
About XTL Biopharmaceutica Financial Statements
XTL Biopharmaceutica stakeholders use historical fundamental indicators, such as XTL Biopharmaceutica's Operating Cycle, to determine how well the company is positioned to perform in the future. Although XTL Biopharmaceutica investors may analyze each financial statement separately, they are all interrelated. For example, changes in XTL Biopharmaceutica's assets and liabilities are reflected in the revenues and expenses on XTL Biopharmaceutica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in XTL Biopharmaceuticals Ltd. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 72.11 | 68.50 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out the analysis of XTL Biopharmaceutica Correlation against competitors. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. Anticipated expansion of XTL directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive XTL Biopharmaceutica assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.76) | Earnings Share (1.15) | Revenue Per Share | Return On Assets | Return On Equity |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, XTL Biopharmaceutica's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.